目的 探讨平消胶囊联合米非司酮治疗子宫肌瘤的临床效果。方法 选取2015年6月—2017年6月衡水市第二人民医院收治的134例子宫肌瘤患者，随机分为对照组和治疗组，每组各67例。对照组口服米非司酮片，自月经来潮第2天开始，25 mg/次，1次/d。治疗组在对照组治疗基础上口服平消胶囊，1.38 g/次，3次/d。两组均连续治疗3个月。观察两组的临床疗效，同时比较两组治疗前后卵泡生成激素（FSH）、孕酮（P）、雌二醇（E₂）、子宫肌瘤体积、白细胞介素（IL）-6、CD³⁺ T细胞百分率、CD⁴⁺/CD⁸⁺比值、孕激素受体（PR）、表皮生长因子受体（EGFR）表达强度。结果 治疗后，对照组和治疗组患者的总有效率分别为80.6%、91.0%，两组比较差异有统计学意义（P<0.05）。治疗后，血清FSH、E₂、P水平、肌瘤体积、IL-6、PR和EGFR表达强度均较治疗前显著降低，外周血CD³⁺、CD⁴⁺/CD⁸⁺值均明显增加，同组治疗前后比较差异均具有统计学意义（P<0.05）；治疗后，治疗组FSH、E₂、P水平、肌瘤体积、IL-6、PR和EGFR表达强度均显著低于对照组，外周血CD³⁺、CD⁴⁺/CD⁸⁺值高于对照组，两组比较差异具有统计学意义（P<0.05）。结论 平消胶囊联合米非司酮治疗子宫肌瘤具有较好的临床疗效，可有效缓解患者症状体征，调控机体性激素水平，提高免疫功能，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Pingxiao Capsules combined with mifepristone in treatment of uterine fibroids. Methods Patients (134 cases) with uterine fibroids in the Second People's Hospital of Hengshui from June 2015 to June 2017 were randomly divided into control (67 cases) and treatment (67 cases) groups. Patients in the control group were po administered with Mifepristone Tablets since the second day of menstruation, 25 mg/time, once daily. Patients in the treatment group were po administered Pingxiao Capsules on the basis of the control group, 1.38 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the changes of FSH, P, E₂, volume of uterine fibroids, IL-6, percentage of CD³⁺ T cells, CD⁴⁺/CD⁸⁺, expression intensity of PR and EGFR in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 80.6% and 91.0%, respectively, and there was difference between two groups (P < 0.05). After treatment, FSH, P, E₂, volume of uterine fibroids, IL-6, expression intensity of PR and EGFR in two groups were decreased, but percentage of CD³⁺ T cells, CD⁴⁺/CD⁸⁺ were increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, FSH, P, E₂, volume of uterine fibroids, IL-6, expression intensity of PR and EGFR in the treatment group were lower than those in the control group, but CD³⁺ T cells, CD⁴⁺/CD⁸⁺ were higher than those in the treatment group, and there was difference between two groups (P < 0.05). Conclusion Pingxiao Capsules combined with mifepristone has clinical curative effect in treatment of uterine fibroids, and can relieve symptoms and signs of patients effectively, also can regulate the level of sex hormones and improve immune function, which has a certain clinical application value.